Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2008 3
2009 4
2010 2
2011 3
2012 1
2014 2
2015 3
2018 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM).
Meynard JL, Moinot L, Landman R, Morand-Joubert L, Besseghir A, Kolta S, Spire B, Todesco E, Bouchaud O, Fagard C, Chene G, Girard PM; ANRS 140 DREAM Study Group. Meynard JL, et al. J Antimicrob Chemother. 2018 Jun 1;73(6):1672-1676. doi: 10.1093/jac/dky055. J Antimicrob Chemother. 2018. PMID: 29584910 Clinical Trial.
Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
Vassallo M, Durant J, Lebrun-Frenay C, Fabre R, Ticchioni M, Andersen S, DeSalvador F, Harvey-Langton A, Dunais B, Cohen-Codar I, Montagne N, Cua E, Fredouille-Heripret L, Laffon M, Cottalorda J, Dellamonica P, Pradier C. Vassallo M, et al. Among authors: cohen codar i. HIV Med. 2015 Aug;16(7):431-40. doi: 10.1111/hiv.12246. Epub 2015 May 18. HIV Med. 2015. PMID: 25981452 Free article.
Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF; MONARK Study Group. Ghosn J, et al. Among authors: cohen codar i. HIV Med. 2010 Feb;11(2):137-42. doi: 10.1111/j.1468-1293.2009.00752.x. Epub 2009 Aug 13. HIV Med. 2010. PMID: 19682100 Free article. Clinical Trial.
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
Lambert-Niclot S, Masquelier B, Cohen Codar I, Soulie C, Delaugerre C, Morand-Joubert L, Charpentier C, Ferre V, Plantier JC, Montes B, Carret S, Perrot V, Peytavin G, Costagliola D, Calvez V, Marcelin AG; EOLE Study Group. Lambert-Niclot S, et al. Among authors: cohen codar i. J Antimicrob Chemother. 2012 Oct;67(10):2487-93. doi: 10.1093/jac/dks226. Epub 2012 Jun 25. J Antimicrob Chemother. 2012. PMID: 22733652
19 results